day one thursday 13 june 2019 · 2019-06-11 · 1. baso pan tumour special session (violet badge -...

CANCER COLLABORATION FRINGE MEETINGS (STRICTLY INVITATION ONLY)08:30 – 12:00

REGISTRATION OPENS12:00 – 13:00

LUNCH, EXHIBITION & CHARITY CORNER - DURHAM & CAMBRIDGE SUITE12:00 – 13:00

WELCOME & INTRODUCTION TO PROFESSOR RICHARD SULLIVAN BY PROFESSOR DANIEL HOCHHAUSER, VICE CHAIR – OXFORD SUITE13:00 – 14:00

COFFEE, EXHIBITION & CHARITY CORNER – DURHAM & CAMBRIDGE SUITE14:00 – 14:25

DIVISION BELL - PROFESSOR DANIEL HOCHHAUSER, CHAIR – OXFORD SUITE17:30 – 18:45

CONFERENCE DINNER, OXFORD SUITE, HILTON BRIGHTON20:00 – 22:30

BREAST

BASO Cancer Surgical Session

BLADDER & KIDNEY

COLOR-ECTAL

CANCERGYNAE LUNG

MELA-NOMA

PROSTATERADIO-

THERAPY

UKONS –delivering care to the

cancer patient

LIVER CANCER/UPPER GI

How to engage

and work with PC in

cancer

14:30 17:25

DAY ONE – THURSDAY 13TH JUNE 2019

PLATINUM SPONSOR – NOVARTIS MELANOMA SYMPOSIUM – DR PAUL NATHAN, CHAIR11:45 – 12:45

ARRIVAL, COFFEE, TEA,BREAKFAST ROLLS, EXHIBITION & CHARITY CORNER – DURHAM & CAMBRIDGE SUITE07:15 – 08:30

OPTIONAL INDUSTRY COMPLIMENTARY WORKSHOP – PROFESSOR DAME LESLEY FALLOWFIELD “RISK & UNCERTAINTY IN MEDICINE09:15 – 10:15

COFFEE, EXHIBITION & CHARITY CORNER – DURHAM & CAMBRIDGE SUITE10:15– 11:25

INTRODUCTION TO PROFESSOR DAVID SPIEGELHALTER, PROFESSOR RUTH PLUMMER CHAIR – OXFORD SUITE12:15 – 13:15

LUNCH, EXHIBITION & CHARITY CORNER – DURHAM & CAMBRIDGE SUITE13:15 – 14:15

OPTIONAL HCP WORKSHOP – “HOW TO ENGAGE AND WORK WITH PRIMARY CARE” – BY MACMILLAN GP13:30 – 14:30

DEPARTURESFrom 13:15

DAY TWO – FRIDAY 14TH JUNE 2019

WELCOME, PROFESSOR RUTH PLUMMER, CHAIR – OXFORD SUITE08:30 – 8:35

BREAST

Treating the Older

Cancer Patient

BLADDER & KIDNEY

COLOR-ECTAL

CANCERGYNAE LUNG

MELA-NOMA

PROSTATERADIO-

THERAPY

UKOMiC –Oral Cancer

Care

LIVER CANCER/UPPER GI

How to engage

and work with PC in

cancer

08:35 12:10

Clinical Stream Colours

DAY ONE CLINICAL STREAMS

1. BASO PAN TUMOUR SPECIAL SESSION (VIOLET BADGE - DAY ONE ONLY)

2. BLADDER & KIDNEY JOINT SESSION (MAGENTA BADGE)

3. BREAST (PINK BADGE

4. COLORECTAL CANCER (BADGE COLOUR TBC)

5. HOW TO ENGAGE AND WORK WITH PRIMARY CARE IN CANCER (GREEN BADGE)

6. GYNAECOLOGY (BLUE BADGE)

7. LIVER CANCER – UPPER GI (ORANGE BADGE)

8. LUNG (YELLOW BADGE)

9. MELANOMA (CYAN BADGE)

10. PROSTATE (RED BADGE)

11. RADIOTHERAPY (WHITE BADGE)

12. UKONS (BADGE COLOUR TBC - DAY ONE ONLY)

DAY TWO CLINICAL STREAMS

1. BLADDER & KIDNEY JOINT SESSION (MAGENTA BADGE)

2. BREAST (PINK BADGE)

3. COLORECTAL CANCER (BADGE COLOUR TBC)

4. HOW TO ENGAGE AND WORK WITH PRIMARY CARE IN CANCER (GREEN BADGE)

5. GYNAECOLOGY (BLUE BADGE)

6. LIVER CANCER – UPPER GI (ORANGE BADGE)

7. LUNG (YELLOW BADGE)

8. MELANOMA (CYAN BADGE)

9. PROSTATE (RED BADGE)

10. RADIOTHERAPY (WHITE BADGE)

11. TREATING THE OLDER CANCER PATIENT (VIOLET BADGE DAY TWO ONLY)

12. UKOMiC – Oral Cancer Care (BADGE COLOUR TBC - DAY TWO ONLY)

SESSION MEETING ROOM

PLENARY MEETING ROOM OXFORD SUITE

EXHIBITION ROOM DURHAM & CAMBRIDGE SUITE

BASO PAN TUMOUR SURGICAL SESSION BALMORAL

BLADDER & KIDNEY JOINT SESSION HALL 4

BREAST CLARENCE

COLORECTAL CANCER PRESTON

HOW TO ENGAGE AND WORK WITH

PRIMARY CARE IN CANCER?

GLOUCESTER

GYNAECOLOGY OSBORNE

LIVER CANCER (UPPER GI) LANCASTER

LUNG STANMER

MELANOMA QUEENS

PROSTATE SANDRINGHAM

RADIOTHERAPY BUCKINGHAM

UKONS AMBASSADOR

SESSION MEETING ROOM

PLENARY MEETING ROOM OXFORD SUITE

EXHIBITION ROOM DURHAM & CAMBRIDGE SUITE

BLADDER & KIDNEY JOINT SESSION HALL 4

BREAST AMBASSADOR

COLORECTAL CANCER PRESTON

GYNAECOLOGY OSBORNE

HOW TO ENGAGE AND WORK WITH PRIMARY

CARE CANCER (OPTIONAL HCP WORKSHOP)

BALMORAL

LIVER CANCER (UPPER GI) LANCASTER

LUNG STANMER

MELANOMA QUEENS

PROSTATE SANDRINGHAM

RADIOTHERAPY BUCKINGHAM

RISK AND UNCERTAINTY IN MEDICINE (OPTIONAL

INDUSTRY AND CHARITIES ONLY )

OXFORD SUITE

TREATING THE OLDER CANCER PATIENT CLARENCE

UKOMIC GLOUCESTER

Thursday 13.06.19 Friday 14.06.19

2019 UK ONCOLOGY FORUMPLENARY DAY ONE – THURSDAY 13TH JUNE 2019 - OVERVIEWOXFORD SUITE, HILTON BRIGHTON METROPOLE

DAY ONE SPEAKER SUBJECT

08:30hrs ~ 12:00hrs Cancer Collaboration Fringe Meetings (strictly by invitation only)

11:45hrs ~ 12:45hrs Dr Paul Nathan, Chair Novartis Melanoma Symposium (all welcome)

12:00hrs Registration, exhibition and lunch in the Durham & Cambridge Suite

13:00hrs Professor Daniel HochhauserVice Chair of the UK Oncology Forum

Welcome – main plenary, Oxford Suite

13:15hrs ~ 13:55hrs Professor Richard Sullivan Universal Health Coverage and the Future of Global Cancer

14:00hrs ~ 14:25hrs All Coffee, tea & exhibition in the Durham & Cambridge Suite

14:30hrs ~ 17:25hrs Clinical breakouts please ensure you register for a different workshop on day 2 – tumour specific workshops will be repeated on day 2

17:30hrs ~ 18:45hs Professor Daniel Hochhauser (Chair)Professor Karl Claxton (Panellist)Dr Rachel Clarke (Panellist)Professor Richard Sullivan (Panellist)George Alagiah (Panellist)

Division Bell

18:45hrs Check-in hotels

20:00hrs ~ 22:30hrs Conference dinner in the Oxford Suite, Hilton Metropole


TIMINGS (14:30hrs ~ 17:30hrs) Synopsis: The British Association of Surgical Oncology ~ Association of Cancer Surgeons is working with the Oncology Symposium as a new venture to provide a Surgical Focus within the meeting.The session will be chaired by Professor Robert Kirby, President BASO~ACS and Professor Michael Douek, Meeting Secretary BASO~ACSThe first part of the session will be surgical cancer specialists’ views on Neoadjuvant Chemotherapy. There will be a debate between Mr Charlie Chan, Consultant Breast Surgeon and Prof Jayant Vaidya, Prof of Surgery and Oncology, UCL “Neoadjuvant should be preferred to adjuvant chemotherapy in early breast cancer” followed by talks by Professor Dion Morton, Barling Professor of Surgery, University of Birmingham on Neoadjuvant chemotherapy for bowel cancer and by Professor Tim Underwood, Professor of Gastrointestinal Surgery, University of Southampton on Neoadjuvant chemotherapy in oesophageal cancer. This will be followed by a panel discussion.Following coffee we are delighted to have Professor Cornelis van de Velde , Professor of Surgical Oncology, Leiden University Medical Center, The Netherlands talk to us on ‘Surgery for cancer in the 21st century ‘ He will talk about prospects for the future, and share his expertise in proteomics and biomarkers.This session comes with a surgical bias, but is aimed at anyone involved in the treatment of solid cancers. We hope that we will have the pleasure of your company!(Please note the annual BASO~ACS meeting will be held in the Law Society, London, 17 – 18 November)

14:30hrs ~ 14:35hrs (5 mins) Professor Robert Kirby, President BASO~ACSProfessor Michael Douek, Meeting Secretary BASO~ACS

Welcome

14:35hrs ~ 15:20hrs (45 mins) Mr Charlie Chan, Consultant Breast SurgeonProf Jayant Vaidya, Prof of Surgery and Oncology, UCL

DEBATE Session: “Neoadjuvant should be preferred to adjuvant chemotherapy in early breast cancer”

(14:35-14:50) For: Mr Charlie Chan, Consultant Breast Surgeon (15 mins)(14:50-15:05) Against: Prof Jayant Vaidya, Prof of Surgery and Oncology, UCL (15 mins)(15:05-15:20) Discussion (15 mins)

15:20hrs ~ 15:40hrs (20 mins) Professor Dion MortonBarling Professor of Surgery, University of Birmingham

Neoadjuvant chemotherapy for bowel cancer

15:40hrs – 16:00hrs (20 mins) Professor Tim UnderwoodProfessor of Gastrointestinal Surgery, University of Southampton

Neoadjuvant chemotherapy in oesophageal cancer

16:00hrs – 16:30hrs (30 mins) Chair: Professor Robert Kirby, President BASO~ACS Panel discussion

16:30hrs – 16:40hrs (10 mins) All Coffee, tea & exhibition in the Durham & Cambridge Suite

16:40hrs – 17:20hrs (40 mins) Professor Cornelis van de VeldeProfessor of Surgical Oncology, Leiden University Medical CenterThe Netherlands

Invited Lecture: ‘Surgery for cancer in the 21st century ‘

17:20hrs – 17:25hrs (5 mins) Chairman’s thoughts, evaluation and wrap up

17:25hrs All Main plenary Room , Oxford Suite for Division Bell Session

BASO CANCER SESSIONThursday 13th June 2019 – Day One OnlyWORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY

DAY ONE DAY TWO SPEAKER SUBJECT

TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs)

Synopsis: Bladder cancer remains the most expensive cancer to treat in terms of follow up . State of the art surgical and non surgical techniques can be considered for many patients with localised muscle invasive disease but which is better? Can we easily compare the two and how should we advise patients.Little improvements have been seen over the last 20 years in terms of survival for advanced disease however the advent of immunotherapy in urothelial cancer has given new promise. Who should we treat and how.Upper tract urothelial cancer has had little in the way of progress and few randomised trials but adjuvant therapy has been shown to improve outcome- how has this happenedRenal cancer has had an explosion of new therapies over the last 10 years, how should we think about adding in immunotherapy and how does this improve outcome. Is nephrectomy still gold standard for patients with advanced or metastatic disease.Many questions but you can hope to find some of the answers ( or even more questions) in the Oncology Forum Bladder/Renal Track

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs – 08:50hrs (5 mins) Dr Alison Birtle (Chair) / Dr Philip Savage (Chair) Welcome

14:35hrs ~ 15:00hrs (25 mins) 08:50hrs ~ 09:15hrs (25 mins) Dr Bernadett Szabados Immunotherapy in bladder and renal

15:00hrs ~ 15:05hrs (5 mins) 09:15hrs ~ 09:20hrs (5 mins) Dr Alison Birtle (Chair) / Dr Philip Savage (Chair) Q&A

15:05hrs ~ 15:30hrs (25 mins) 09:20hrs ~09:45hrs (25 mins) Dr Shaista Hafeez Bladder preservation and markers

15:30hrs ~ 15:35hrs (5 mins) 09:45hrs ~ 09:50hrs (5 mins) Dr Alison Birtle (Chair) Q&A

15:35hrs ~ 16:00hrs (25 mins) 09:50hrs ~ 10:15hrs (25 mins) Professor John Kelly Cystectomy

16:00hrs ~ 16:05hrs (5 mins) 10:15hrs ~ 10:20hrs (5 mins) Dr Alison Birtle (Chair) Q&A

16:05hrs ~ 16:15hrs (10 mins) 10:20hrs ~ 10:50hrs (30 mins) All Coffee, tea & exhibition in the Durham & Cambridge Suite

16:15hrs ~ 16:40hrs (25 mins) 10:50hrs ~ 11:15hrs (25 mins) Professor David Nicol Cytoreduction in a new era

16:40hrs ~ 16:45hrs (5 mins) 11:15hrs ~ 11:20hrs (5 mins) Dr Philip Savage (Chair) Q&A

16:45hrs ~ 16:55hrs (10 mins) 11:20hrs ~ 11:35hrs (15 mins) Dr Bernadett Szabados Bladder & Renal ASCO Highlights

16:55hrs ~ 17:10hrs (15 mins) 11:35hrs ~ 11:55hrs (20 mins) Dr Alison Birtle Adjuvant chemotherapy for all in upper tract TCC

17:10hrs ~ 17:20hrs (10 mins) 11:55hrs ~ 12:05hrs (5 mins) Expert Panel Discussion

17:20hrs ~ 17:25hrs (5 mins) 12:05hrs ~ 12:10hrs (5 mins) Dr Alison Birtle (Chair) / Dr Philip Savage (Chair)) Chairman’s thoughts, evaluation and wrap up

17:30hrs 12:15hrs All Main plenary – Oxford Suite

BLADDER & KIDNEY JOINT SESSIONThursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY

BREAST CANCER SESSIONThursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY


TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs) Synopsis: Breast Cancer Session ; When Less is More-But Recognising When It Is NotWe are increasingly looking to tailor treatment to reduce over-treatment or under-treatment in breast cancer. In older patients we have sometimes tailored treatment to reduce harm – the National Audit in Older Breast Cancer Patients (NABCOP) reports on treatments and outcomes . Recent studies and publications in all the sub-specialities look to de-escalate treatment when safe (or at least “ non-inferior”) and escalate where there are further gains for patients. This session will examine where we are with these strategies from leading experts in medical oncology, clinical oncology and surgery. On a background of improving mortality from breast cancer are we at risk of pulling too far back for some patients? Conversely- are we treating excessively for small gains for others (and at what cost to our patients and/or our limited resources) ? does surgical de-escalation always make sense over radiotherapy escalation ? Can we simultaneously de-escalate systemic therapy and surgery ? come to hear our expert panel opinions on when less is more-but recognising when it is not (or never is)!

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs ~08:50hrs (5 mins) Dr Marina Parton (Chair) Welcome

14:35hrs ~ 14:55hrs (20 mins) 08:50hrs ~ 09:10hrs (20 mins) Professor David Dodwell De-escalation of local treatment in older patients

14:55hrs ~ 15:00hrs (5 mins) 09:10hrs ~ 09:15hrs (5 mins) Dr Marina Parton (Chair) Q&A

15:00hrs ~ 15:25hrs (25 mins) 09:15hrs ~ 09:40hrs (25 mins) Dr Mark Verrill A year in review; Data from around the world to your clinic


15:30hrs ~ 15:50hrs (20 mins) 09:45hrs ~ 10:10hrs (25 mins) Dr Anna Kirby More or less – tailoring breast radiation to risk


15:55hrs ~ 16:00hrs (5 mins) 10:15hrs ~ 10:40hrs (25 mins) Coffee, tea & exhibition in the Durham & Cambridge Suite

16:00hrs ~ 16:25hrs (25 mins) 10:40hrs ~ 11:05hrs (25 mins) Mr Paul Thiruchelvam De-escalation in surgery – the evidence


16:30hrs ~ 17:00hrs (30 mins) 11:10hrs ~ 11:40hrs (30 mins) Michael Gnant Perspectives on systemic therapy de-escalation (and when to escalate)


17:10hrs ~ 17:20hrs (10 mins) 11:45hrs ~ 12:05hrs (20 mins) Expert Panel Case histories and discussion. Cases presented by Dr Parton and Dr Verill

17:20hrs ~ 17:25hrs (5 mins) 12:05hrs ~ 12:10hrs (5 mins) Dr Marina Parton (Chair) Chairman’s thoughts, evaluation and wrap up



TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs) “UPDATES IN COLORECTAL AND ANAL CANCER”Synopsis: There has been a dearth of new drug approvals in lower gastrointestinal cancer in comparison to most cancer sites over the last few years. Despite this, significant advances in the management of colorectal and anal cancer are being made. This includes innovative multi-modality therapies, novel therapeutic approaches using the neoadjuvant setting, international collaboration in rare as well as common tumour trials, and investigation of ‘liquid biopsies’. In this session, Elske Gootjes will give us an update on multimodality approaches to optimal debulking of metastatic colorectal cancer; Duncan Gilbert will discuss multimodality management of anal cancer; Jenny Seligmann will update us on neoadjuvant trial results and trial concepts in this setting in both colon and rectal cancer; Vicky Coyle will discuss updates in use of ctDNA and proposed international trials and Janet Graham will give us an update from ASCO 2019, where results from UK and international colorectal cancer trials were presented.

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs ~ 08:50hrs (5 mins) Professor Richard Wilson (Chair) Welcome

14:35hrs ~ 14:55hrs (20 mins) 08:50hrs ~ 09:15hrs (20 mins) Dr Elske Gootjes Maximal debulking in metastatic colorectal cancer

14:55hrs ~ 15:00hrs (5 mins) 09:15hrs ~ 09:20hrs (5 mins) Professor Richard Wilson (Chair) Q&A

15:00hrs ~ 15:20hrs (20 mins) 09:20hrs ~ 09:40hrs (20 mins) Dr Jenny `Seligmann Neoadjuvant approaches to colon and rectal cancer


15:25hrs ~ 15:45hrs (20 mins) 09:45hrs ~ 10:05hrs (20 mins) Dr Duncan Gilbert Updates in anal cancer


15:50hrs ~ 16:10hrs (20 mins) 10:10hrs ~ 10:30hrs (20 mins) Prof Vicky Coyle The role of ctDNA in colorectal cancer



16:25hrs ~ 16:45hrs (20 mins) 11:05hrs ~ 11:25hrs (20 mins) Dr Janet Graham ASCO 2019 lower GI cancer highlights

16:45hrs ~ 16:50 hrs (5 mins) 11:25hrs ~ 11:30hrs (5 mins) Professor Richard Wilson (Chair) Q&A


17:15hrs ~ 17:20hrs (5 mins) 12:00hrs ~ 12:05hrs Professor Richard Wilson (Chair) Chairman’s thoughts, evaluation and wrap up


COLORECTAL CANCER SESSIONThursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY


TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs) Synopsis: This year’s gynaecological track of the UK Oncology Forum is very pleased to have, once again, an illustrious, highly experienced panel of speakers: Dr Andrew Clamp (UK), Professor Marcia Hall (UK), Mr Ranjit Manchanda (UK), Dr Remi Nout (Netherlands) and Dr Melanie Powell (UK). Each one will highlight areas of controversy and evolving gynaecological cancer research and practice relevant to the UK population. Particular focus will be given to initiatives that will identify new treatment paradigms for patients with rare gynaecological cancer, the rapidly expanding portfolio of promising endometrial clinical trials, the molecular basis of our progress in endometrial cancer and how this will continue to crystallize our ability to correctly select patients as well as recent developments in surgical approaches for early stage cervical cancer and intra-peritoneal chemotherapy. We welcome robust interaction with the audience that enables us all to return back to our clinical practice with increased knowledge, ideas, collaboration and motivation to improve what we are doing a little bit more.

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs ~ 08:50hrs (5 mins) Dr Rebecca Kristeleit (Chair) Welcome

14:35hrs ~ 15:00hrs (25 mins) 08:50hrs ~ 09:15hrs (25 mins) Dr Marcia Hall RANGO and background to this trial ie needs of the rare gynae population and the anticipated potential of the trial to help change the treatment landscape of rare gynae cancers

15:00hrs ~ 15:05hrs (5 mins) 09:15hrs ~ 09:20hrs (5 mins) Dr Rebecca Kristeleit (Chair) Q&A

15:05hrs ~ 15:30hrs (25 mins) 09:20hrs ~ 09:45hrs (25 mins) Dr Andrew Clamp UK endometrial cancer trial portfolio and the rapid developments in this area


15:35hrs ~ 16:00hrs (25 mins) 09:50hrs ~ 10:15hrs (25 mins) Dr Melanie Powell (day 1 only)Prof Remi Nout (Day 2 only)

UK endometrial cancer trial portfolio and the rapid developments in this areaGCIC endometrial cancer translational research overview


16:05hrs ~ 16:30hrs (25 mins) 10:20hrs ~ 10:45hrs (25 mins) Dr Melanie Powell LACC trial results from the radiotherapist perspective and emerging data for immunotherapy or other notable developments in cervical cancer

10:45hrs ~ 10:50hrs (5 mins) Dr Rebecca Kristeleit (Chair) Q&A


16:35hrs ~ 17:00hrs (25 mins) 11:15hrs ~ 11:40hrs (25 mins) Dr Ranjit Manchandra Debate/present the arguments for/against HIPEC in first line ovarian cancer and also present an analytical summary of the findings of the LACC trial


17:05hrs ~ 17:20hrs (15 mins) 11:45hrs ~ 12:05hrs (20 mins) All Panel discussion

17:20hrs ~ 17:25hrs (5 mins) 12:05hrs ~ 12:10hrs (5 mins) Dr Rebecca Kristeleit (Chair) Chairman’s thoughts, evaluation and wrap up


GYNAECOLOGY CANCER SESSIONThursday 13th & Friday 14th June 2019


TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs) Synopsis: As the number of PLWC is increasing and treatments for cancer are changing and becoming more complex, effective working between Primary and Secondary care is vital for patients to experience safe and seamless support through their cancer journey. For this to happen, good communication between professionals in different care settings is essential but unfortunately this isn't always the experience that people describe. Another important element is to ensure that Primary Care teams feels confident to better support PLWC in the community and are provided with the education and tools to do this - this is central to our role at Macmillan Cancer Support; what needs to be

done to improve working between care settings and truly bridge the gap to improve care for PLWC in a changing landscape.

14:30hrs ~ 14:35hrs (5mins) 08:45hrs ~ 08:50hrs (5 mins) Dr Rosie Loftus (Chair) Welcome

14:35hrs ~ 15:00hrs (25 mins) 08:50hrs ~ 09:15hrs (25 mins) Dr Sinead ClarkeMacmillan GP Adviser

The changing cancer story and implications for primary care - and transitions of care between primary/secondary/tertiary

15:00hrs ~ 15:05hrs (5 mins) 09:15hrs ~ 09:20hrs (5 mins) Dr Rosie Loftus (Chair) Q&A

15:05hrs ~ 15:30hrs (25 mins) 09:20hrs ~ 09:45hrs (25 mins) Dr Anthony CunliffeMacmillan GP Adviser

Quality Toolkit/RBY(integrated care models/PCH work(working with GP networks) - essentially Macmillan working to ensure everyone ready to support PLWC in view of the above


15:35hrs ~ 16:00hrs (25 mins) 09:50hrs ~ 10:15hrs (25 mins) Dr Ashling LillisMacmillan Consultant

The acutely unwell patient - introducing this concept and why important for us all - acute oncology-presentations as new diagnosis/side effects of treatment /EOL



16:20hrs ~ 16:45hrs (25 mins) 11:00hrs ~ 11:25hrs (25 mins) Sophia NicolaMacmillan Primary Care Adviser

Education - presenting resources/ showing how we are supporting professionals and including Gateway C



17:10hrs ~ 17:15hrs (5 mins) 12:00hrs ~ 12:05hrs (5 mins) Dr Rosie Loftus (Chair) Chairman’s thoughts, evaluation and wrap up


HOW TO ENGAGE AND WORK WITH PRIMARY CARE CANCER (MACMILLAN GP)Thursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY


TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs) Title: Update on the management of primary liver cancers.Synopsis: This session aims to discuss treatment options for patients with primary liver cancers with updates on the indications for and outcomes for surgical intervention, the role of the interventional radiologist in the management of these cancers, decision making around appropriate approaches to treatment and recent developments in systemic therapy for primary liver malignancies.This will be an interactive session where possible using clinical cases to illustrate approaches to treatment.

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs ~ 08:50hrs (5 mins) Dr Martin Eatock (Chair) Welcome

14:35hrs ~ 15:00hrs (25 mins) 08:50hrs ~ 09:15hrs (25 mins) Professor Daniel Palmer (TBC) HCC (Oncologists know best)

15:00hrs ~ 15:05hrs (5 mins) 09:15hrs ~ 09:20hrs (5 mins) Dr Martin Eatock (Chair) Q&A

15:05hrs ~ 15:30hrs (25 mins) 09:20hrs ~ 09:45hrs (25 mins) Dr Peter Kennedy Image Guided Surgery has primacy for primary liver cancer


15:35hrs ~ 16:00hrs (25 mins) 09:50hrs ~ 10:15hrs (25 mins) Mr Hassan Malik Surgical update in primary liver cancer



16:15hrs ~ 16:35hrs (20 mins) 10:50hrs ~ 11:15hrs (25 mins) Dr Rebecca Goody SBRT


16:40hrs ~ 17:05hrs (25 mins) 11:20hrs ~ 11:45hrs (25 mins) Professor Helen ReevesHCC-UK

Update on biomarkers from the HCC-UK Educational Lead


17:10hrs ~17:20hrs (10 mins) 11:50hrs ~ 12:05hrs (15 mins) Expert Panel Discussion

17:20hrs ~ 17:25hrs (5 mins) 12:05hrs ~ 12:10hrs (5 mins) Dr Martin Eatock (Chair) Chairman’s thoughts, evaluation and wrap up


LIVER CANCER SESSION (UPPER GI)Thursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY

LUNG CANCER SESSIONThursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY


TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs) Synopsis : It is an exciting time to be involved in the care of lung cancer patients. Rapid progress has been made in the last decade in the field of lung cancer therapy leading to improvement in survival for all stages of disease. One of the most exciting news this year is that improvement in survival has finally been reported in stage 3 NSCLC with the addition of immunotherapy to chemo-radiotherapy. In this year's dynamic session at the Oncology Forum, we have great speakers who will discuss controversies in the field of stage 3 disease, using case based discussions. They will give you the perspective of the clinical oncologist, medical oncologist and the surgeon, which of course can be quite different! We will also be taking a look towards the future with a talk on ‘demystifying biomarkers science’ and another on trendy

‘big data’. Please come prepared to be entertained and to have your current thinking challenged!

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs ~ 08:50hrs (5 mins) Professor Corinne Faivre-Finn (Chair) Welcome – Part 1 Controversies in Stage III NSCLC – Role of surgery and Radiotherapy in the era of IOCase based presentations Covering the “Grey Zones”

14:35hrs ~ 15:00hrs (25 mins) 08:50hrs ~ 09:15hrs (25 mins) Professor Paul Van Schil The Surgical View

15:00hrs ~ 15:05hrs (5 mins) 09:15hrs ~ 09:20hrs (5 mins) Professor Corinne Faivre-Finn (Chair) Q&A

15:05hrs ~ 15:30hrs (25 mins) 09:20hrs ~ 09:45hrs (25 mins) Dr Fiona McDonald The Radiotherapists view


15:35hrs ~ 16:00hrs (25 mins) 09:50hrs ~ 10:15hrs (25 mins) Dr Alastair Greystoke The Medical Oncologist view



Professor Corinne Faivre-Finn (Chair) Welcome back – Part 2 - Looking towards the future

16:10hrs ~ 16:35hrs (25 mins) 10:50hrs ~ 11:15hrs (25 mins) Dr Andrew Hudson Demystifying Translational Science


16:40hrs ~ 17:05hrs (25 mins) 11:20hrs ~ 11:45hrs (25 mins) Professor Phillipe Lambin Looking towards the future in Lung Cancer - Big data (radiomics, AI, Decision aids)


17:10hrs ~ 17:20hrs (10 mins) 11:50hrs ~ 12:05hrs (15 mins) Expert Panel Panel Discussion

17:20hrs ~ 17:25hrs (5 mins) 12:05hrs ~ 12:10hrs (5 mins) Professor Corinne Faivre-Finn (Chair) Chairman’s thoughts, evaluation and wrap up



TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs) Synopsis: The Melanoma Session this year will cover a breadth of topical subjects for all those who treat patients with or have an interest in melanoma. Veronique Bataille will discuss genetic predisposition to melanoma and toxicity management of new drug, Sophie Papa will discuss the promise of game-changing cell-based therapies, Joe Sacco will update on Uveal Melanoma - an area of major unmet clinical need, and Heather Shaw will discuss her selection of melanoma related practice changing news from ASCO.

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs ~ 08:50hrs (5 mins) Dr Paul Nathan (Chair) Welcome

14:35hrs ~ 15:00hrs (25 mins) 08:50hrs ~ 09:15hrs (25 mins) Dr Joseph Sacco Uveal

15:00hrs ~ 15:05hrs (5 mins) 09:15hrs ~ 09:20hrs (5 mins) Dr Paul Nathan (Chair) Q&A

15:05hrs ~ 15:30hrs (25 mins) 09:20hrs ~ 09:45hrs (25 mins) Dr Sophie Papa Adoptive cell therapy


15:35hrs ~ 16:00hrs (25 mins) 09:50hrs ~ 10:15hrs (25 mins) Dr Veronique Bataille Skin toxicity of systemic agents



16:20hrs ~ 16:45hrs (25 mins) 10:50hrs ~ 11:15hrs (25 mins) Dr Heather Shaw ASCO highlight and insights on Melanoma


16:50hrs ~ 17:15hrs (25 mins) 11:20hrs ~ 12:00hrs (40 mins) All Panel Discussion

17:15hrs ~ 17:20hrs (5 mins) 12:00hrs ~12:05hrs (5 mins) Dr Paul Nathan (Chair) Chairman’s thoughts, evaluation and wrap up


MELANOMA CANCER SESSIONThursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY


TIMINGS (14:30hrs ~ 17:30hrs)

TIMINGS (08:45hrs ~ 12:15hrs)

Synopsis: There have been major advances in the management of castrate sensitive metastaitc prostate cancer in the last few years. Data on the use of both Docetaxel and Abiraterone have shown significant improvements in survival. There remains international controversy on how to manage “low volume” metastaitc disease. The most recent STAMPEDE results examined radical therapy to the prostate using radiotherapy for patients with synchronous metastatic disease. This demonstrated a substantial failure-free and overall survival benefit in the subgroup of patients with “low volume” disease. Local RT to the primary tumour should now be the new standard-of-care for men with synchronous oligometastatic prostate cancer.

Trials have shown radiotherapy improves survival in locally-advanced prostate cancer. However, surgery (radical prostatectomy) is now used for the treatment of locally-advanced disease in 1 in 5 such patients, since a significant number of practitioners consider surgery and radiotherapy to be oncologically equivalent, extrapolating from trials of radiotherapy and ADT in high risk localised disease. The session will explore and discuss the challenge of managing high risk localised disease and oligometastatic castrate sensitive disease, specifically looking at the roles of surgery, radiotherapy (both to the primary and to mets) and systemic therapies in this setting.

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs ~ 08:50hrs (5 mins) Dr Nick Van As (Chair) Welcome

14:35hrs ~ 15:05hrs (30 mins) 08:50hrs ~ 09:25hrs (35 mins) Professor Noel W Clarke Management of metastatic disease “low” volume mets – with a surgical overview

15:05hrs ~ 15:10hrs (5 mins) 09:25hrs ~ 09:30hrs (5 mins) Dr Nick Van As (Chair) Q&A

15:10hrs ~ 15:45hrs (45 mins) 09:30hrs ~ 10:05hrs (35 mins) Professor Nicholas James (Day 1)Dr Julia Murray (Day 2)

STAMPEDE results, looking at the management of metastatic disease “low” volume mets



16:05hrs ~ 16:45hrs (40 mins) 10:50hrs ~ 11:30hrs (40 mins) Dr Lisa Pickering ASCO Highlights in prostate cancer


16:50hrs ~ 17:15hrs (25 mins) 11:35hrs ~ 12:00hrs (25 mins) All Panel discussion/debate

17:15hrs ~ 17:20hrs (5 mins) 12:00hrs ~ 12:05hrs (5 mins) Dr Nick Van As (Chair) Chairman’s thoughts, evaluation and wrap up


PROSTATE CANCER SESSIONThursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY


TIMINGS (14:30hrs ~ 17:30hrs) TIMINGS (08:45hrs ~ 12:15hrs) Title : The Radiotherapy RevolutionSynopsis : The key objectives of the Radiotherapy Sessions for 2019 are:Learn how radiotherapy is becoming standard of care in several metastatic scenariosHear about the proton programme and which patients may benefitLearn about the newer radiotherapy technologies including Cyberknife, Linac SBRT and The MR LinacHear about combinations of drugs and radiotherapy which may change the way we treat patients in a variety of cancers

14:30hrs ~ 14:35hrs (5 mins) 08:45hrs ~ 08:50hrs (5 mins) Dr Alison Tree (Chair) Welcome

14:35hrs ~ 15:05hrs (30 mins) 08:50hrs ~ 09:20hrs (30 mins) Dr Alison Tree Radiotherapy for metastatic cancer

15:05hrs ~ 15:10hrs (5 mins) 09:20hrs ~ 09:25hrs (5 mins) Dr Alison Tree (Chair) Q&A

15:10hrs ~ 15:40hrs (30 mins) 09:25hrs ~ 09:55hrs (30 mins) Dr Ann Henry Improving pelvic cancer outcomes with Image Guided Brachytherapy (IGBT)


15:45hrs ~ 16:15hrs (30 mins) 10:00hrs ~ 10:30hrs (30 mins) Dr Katharine AitkenRoyal Marsden, London

Technical advances in radiotherapy



16:35hrs ~ 17:05hrs (30 mins) 11:05hrs ~ 11:35hrs (30 mins) Professor Anthony Chalmers, University of Glasgow (TBC)

Radiotherapy-drug combinations

17:05hrs ~ 17::20hrs (15 mins) 11:35hrs ~ 12:00hrs (25 mins) Expert Panel Discussion

17:20hrs ~ 17:25hrs (5 mins) 12:00hrs ~ 12:05hrs (5 mins) Dr Alison Tree (Chair) Chairman’s thoughts, evaluation and wrap up


RADIOTHERAPY CANCER SESSION (White Badge)Thursday 13th & Friday 14th June 2019WORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY

TREATING THE OLDER CANCER PATIENTFriday 14th June 2019 – Day Two OnlyWORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY

DAY TWO SPEAKER SUBJECT

TIMINGS (08:45hrs ~ 12:15hrs) Synopsis: The majority of cancers occur in older adults. With the growing ageing population, it is important that we provide optimal care and treatment for these patients. This session will cover a multidisciplinary approach in the clinical management of this problem, from the perspectives of oncology and geriatrics. Our panel consists of surgical, radiation and medical oncologists as well as a geriatrician and a geriatric oncology nurse, including the President of the International Society of Geriatric Oncology.

08:45hrs ~ 08:50hrs (5 mins) Professor Kwok-Leung Cheung (Chair) Welcome

08:50hrs ~ 09:10hrs (20 mins) Mr Nicola de’ Liguori-Carino When is too old? Improving outcomes in oncogeriatric surgical patients

09:10hrs ~ 09:15hrs (5 mins) Professor Kwok-Leung Cheung (Chair) Q&A

09:15hrs ~ 09:35hrs (20 mins) Dr Richard Simcock The radiation oncology viewpoint


09:40hrs ~ 10:00hrs (20 mins) Dr Cindy Kenis The importance of geriatric oncology nursing


10:05hrs ~ 10:25hrs (20 mins) Professor Hans Wildiers Cancer in older adults, the medical oncology view


10:30hrs ~ 11:00hrs (30 mins) All Coffee, tea & exhibition in the Durham & Cambridge Suite

11:00hrs ~ 11:05hrs (5 mins) Professor Kwok-Leung Cheung (Chair) Welcome back

11:05hrs ~ 11:30hrs (25 miins) Dr Shane O’Hanlon Fighting fit or frightfully frail -how do I know?


11:35hrs ~ 12:05hrs (30 mins) Expert Panel Discussion

12:05hrs ~ 12:10hrs (5 mins) Professor Kwok-Leung Cheung (Chair) Chairman’s thoughts, evaluation and wrap up

12:15hrs All Main plenary – Oxford Suite


TIMINGS (14:30hrs ~ 17:30hrs) Title : Supporting patients and professionals through changing and challenging times

Synopsis: Both sessions will be very interactive, offering attendee the opportunity to share examples from their practice regarding both topics and help to shape future service delivery at a local level.

Immunotherapy:Biosimilars are entering clinical practice at a fast pace. This session will give an overview of the benefit and impact of biosimilars and work through a real case. It will inform practitioners and managers of the implications of biosimilars in clinical practice.

CRUK Your Cancer Treatment Guide –Practice Implementation:After the session you will have an overview of the role of the UK Chemotherapy Board, including the development of the Treatment Guide. Along with a greater understanding of the importance of sharing information between patients and professions and way to improve the quality of consultations. The session will also outline the importance of continually evaluating changes in practice i.e. implementing the Treatment Guide and the future direction of this Guide.

14:30hrs ~ 14:40hrs (10 mins) Helen Roe (Chair) Welcome

14:40hrs ~ 16:15hrs (35 mins) Elaine Tomlins & Helen Roe Immunotherapy –ISNCC project

16:15hrs ~ 16:30hrs (15 mins) All Coffee & tea

16:30hrs ~ 17:05hrs (35 mins) Catherine Oakley CRUK Your Cancer Treatment Guide –Practice Implementation

17:05hrs ~ 17:20hrs (15 mins) Helen Roe (Chair) Chairman’s thoughts, evaluation and wrap up


UKONS SESSION (this session is designed for cancer nurses)Thursday 13th June 2019 – Day One OnlyWORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY


TIMINGS (08:45hrs ~ 12:15hrs) Synopsis: The United Kingdom Oral Management in Cancer Group (UKOMiC), is a multi-professional group of oral care experts working in oncology and haematology from across the United Kingdom who have come together with the aim of improving oral care in clinical practice. Mindful of the many developments in cancer care aimed at improving survival and quality of life, the correct and consistent approach to managing the multiple oral care problems that can arise still remains a challenge in many clinical settings. We are delighted to be invited by the UK Oncology Forum to deliver this interactive session. The session will be an opportunity for medical, dental, nursing and allied health care professionals working in cancer care to come together to focus on the most up to date understanding and clinical management of oral complications in the cancer setting. The session will be delivered by medical, surgical, dental and nursing experts. During the session we will present and launch the 3rd Edition of the UKOMiC Oral Care Guidance for Cancer and Palliative Care, address the incidence, presentation and management of oral complications seen with the introduction of targeted therapies and immunotherapy, present the prevention, earlier identification and management of osteonecrosis of the jaw and practical tips on care of the oral cavity, before during and after cancer treatments.

08:45hrs ~ 08:50hrs (5 mins) Dr Barry Quinn (Chair) Welcome

08:50hrs ~ 09:15hrs (25 mins) Miss Sonja Hoy TBC

09:15hrs ~ 09:20hrs (5 mins) Dr Barry Quinn (Chair) Q&A

09:20hrs ~ 09:45hrs (25 mins) Joss Barker Talking Mouths - Integrated Care

09:45hrs ~ 09:50hrs (5 mins) Dr Barry Quinn (Chair) Q&A

09:50hrs ~ 10:15hrs (25 mins) Dr Charles Kelly Immunotherapy and toxicity

10:15hrs ~10:20hrs (5 mins) Dr Barry Quinn (Chair) Q&A

10:20hrs ~ 10:50hrs (30 mins) All Coffee, tea & exhibition in the Durham & Cambridge Suite

10:50hrs ~ 11:20hrs (30 mins) Mr Nic Goodger Osteonecrosis of the jaw

11:20hrs ~11:25hrs (5 mins) Dr Barry Quinn (Chair) Q&A

11:25hrs ~ 12:00hrs (35 mins) Speakers/Committee Speaker panel and UKOMiC Committee interactive discussion

12:00hrs ~ 12:05hrs (5 mins) Dr Barry Quinn (Chair) Chairman’s thoughts, evaluation and wrap up


UKOMiC SESSION (treating oral side effects after cancer treatment)Friday 14th June 2019 – Day Two OnlyWORKSTREAM CHOICE - YOU MUST SELECT A DIFFERENT WORKSTREAM PER DAY


07:15hrs ~ 08:25hrs Arrival, coffee, tea, breakfast rolls, Exhibition & Charity Corner – Durham & Cambridge Suite

08:30hrs ~ 08:45hrs Welcome by Professor Plummer in Oxford Suite

08:45hrs ~ 12:10hrs Clinical breakouts

09:15hrs ~ 10:15hrs Professor Dame Lesley Fallowfield Professor of Psycho-oncology at Brighton & Sussex Medical School University of Sussex

Complimentary workshop for industry and charities onlyRisk and Uncertainty in Medicine

10:15hrs ~ 11:25hrs Coffee, tea & exhibition in the Durham & Cambridge Suite

11:00hrs ~ 12:10hrs Clinical Streams

12:15hrs ~ 13:15hrs Professor Sir David Spiegelhalter Communicating risk and uncertainty to cancer patients

13:15hrs ~ 14:15hrs Lunch, Exhibition & Charity Corner – Durham & Cambridge Suite

13:30hrs ~ 14:30hrs GP Macmillan Team (Chair Dr Rosie Loftus) How to engage and work with Primary Care Cancer' sessions – Balmoral Meeting Room

All depart

2019 UK ONCOLOGY FORUMPLENARY DAY TWO – FRIDAY 14TH JUNE 2019 - OVERVIEWOXFORD SUITE, HILTON BRIGHTON METROPOLE

day one thursday 13 june 2019 · 2019-06-11 · 1. baso pan tumour special session (violet badge -...

Documents